Fig. 7

MiR-100-5p inhibits osteogenesis of hBMSCs and angiogenesis of HUVECs by targeting BMPR2 and inhibiting the BMPR2/smad1/5/9 pathway. A The target gene of miR-100-5p was predicted using Targetscan 7.2. B The targeting relationship between miR-100-5p and BMPR2 was verified by a luciferase assay. C Western blotting was used to measure the expression of collagen type 1, BMPR2, SMAD1/5/9, p-SMAD1/5/9, OCN, RUNX2, ALP, OPN, and PPARγ. D Western blotting was used to measure the expression of BMPR2, SMAD1/5/9, p-SMAD1/5/9, FGF2, and VEGFA in HUVECs. E ALP staining of hBMSCs (scale bar = 100 μm). F Alizarin Red S staining of hBMSCs. G Oil Red O staining of hBMSCs (scale bar = 50 μm). H Tube formation assay of HUVECs (scale bar = 200 μm). NC, transfection with NC; siBMPR2, transfection with small interfering RNA of BMPR2; siBMPR2 + antagomiR-100-5p, transfection with small interfering RNA of BMPR2 and antagonist of miR-100-5p; NM-CTL, controls for differentiation. *P < 0.05, versus NC group; #P < 0.05, versus agomiR-100-5p group. NS P>0.05, versus NC group. All data were expressed as mean ± SEM